Levofloxacin Ophthalmic Solution Rx
Generic Name and Formulations:
Levofloxacin (as hemihydrate) 0.5%; oph. soln; contains benzalkonium chloride.
Various generic manufacturers
Indications for Levofloxacin Ophthalmic Solution:
Susceptible bacterial conjunctivitis.
Adults and Children:
<6yrs: not established. ≥6yrs: 1–2 drops in affected eye(s) every 2hrs while awake (max 8 times/day) on days 1 and 2, then 1–2 drops every 4hrs while awake (max 4 times/day) on days 3–7.
Discontinue if superinfection or hypersensitivity occurs. Avoid contact lenses during therapy or if symptomatic. Pregnancy (Cat.C). Nursing mothers.
Transient decreased vision, ocular burning, pain or discomfort, fever, foreign body sensation, headache, pharyngitis, photophobia.
Formerly known under the brand name Quixin.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC